Moderna (MRNA) Doses First Participants in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
Go back to Moderna (MRNA) Doses First Participants in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 63.32 -0.33 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.65 | 52 Week High | $0.52 | |||
| Open | $62.89 | 52 Week Low | $0.08 | |||
| Day High | $63.78 | P/E | N/A | |||
| Day Low | $60.82 | EPS | $-3.80 | |||
| Volume | 4,695,170 | |||||
